MX2007006524A - Metodos para el suministro dirigido de material genetico al higado. - Google Patents

Metodos para el suministro dirigido de material genetico al higado.

Info

Publication number
MX2007006524A
MX2007006524A MX2007006524A MX2007006524A MX2007006524A MX 2007006524 A MX2007006524 A MX 2007006524A MX 2007006524 A MX2007006524 A MX 2007006524A MX 2007006524 A MX2007006524 A MX 2007006524A MX 2007006524 A MX2007006524 A MX 2007006524A
Authority
MX
Mexico
Prior art keywords
methods
gene therapy
liver
genetic material
target organ
Prior art date
Application number
MX2007006524A
Other languages
English (en)
Inventor
Ronald K Scheule
Bradley L Hodges
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2007006524A publication Critical patent/MX2007006524A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

La presente invencion proporciona metodos para la administracion mejorada de varios agentes terapeuticos, tales como agentes para la terapia genica, a la vasculatura de un organo diana en un sujeto mamifero. Se revelan metodos para la terapia de genes diana en el higado de mamifero, en su totalidad o en un solo lobulo hepatico. Los metodos revelados tratan sobre procedimientos basados en cateter minimamente invasores, en donde un organo diana es aislado y tratado localmente con un agente para la terapia genica. Los metodos ofrecen la transfeccion mas eficiente y localizada de tejido, y son adecuados para la terapia genica en sujetos humanos.
MX2007006524A 2004-12-01 2005-12-01 Metodos para el suministro dirigido de material genetico al higado. MX2007006524A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63235904P 2004-12-01 2004-12-01
PCT/US2005/043590 WO2006060641A2 (en) 2004-12-01 2005-12-01 Methods for targeted delivery of genetic material to the liver

Publications (1)

Publication Number Publication Date
MX2007006524A true MX2007006524A (es) 2007-06-22

Family

ID=36565758

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006524A MX2007006524A (es) 2004-12-01 2005-12-01 Metodos para el suministro dirigido de material genetico al higado.

Country Status (7)

Country Link
US (1) US20080025952A1 (es)
EP (1) EP1827502A4 (es)
JP (2) JP2008521575A (es)
CN (1) CN101068575A (es)
BR (1) BRPI0515819A (es)
MX (1) MX2007006524A (es)
WO (1) WO2006060641A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887039T3 (es) 2004-04-21 2021-12-21 Alexion Pharma Inc Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
WO2008138131A1 (en) 2007-05-11 2008-11-20 Enobia Pharma Inc. Bone targeted alkaline phosphatase, kits and methods of use thereof
SG185079A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Internat Sarl Methods, compositions, and kits for the treatment of matrix mineralization disorders
US8738115B2 (en) * 2010-05-11 2014-05-27 Siemens Aktiengesellschaft Method and apparatus for selective internal radiation therapy planning and implementation
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
KR20140084201A (ko) 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
SG10201604810UA (en) * 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10898700B2 (en) 2012-10-26 2021-01-26 Urotronic, Inc. Balloon catheters for body lumens
US10881839B2 (en) 2012-10-26 2021-01-05 Urotronic, Inc. Drug-coated balloon catheters for body lumens
US11938287B2 (en) 2012-10-26 2024-03-26 Urotronic, Inc. Drug-coated balloon catheters for body lumens
WO2014066085A1 (en) 2012-10-26 2014-05-01 Lixiao Wang Drug coated balloon catheters for nonvascular strictures
US10806830B2 (en) 2012-10-26 2020-10-20 Urotronic, Inc. Drug-coated balloon catheters for body lumens
US11504450B2 (en) 2012-10-26 2022-11-22 Urotronic, Inc. Drug-coated balloon catheters for body lumens
US10850076B2 (en) 2012-10-26 2020-12-01 Urotronic, Inc. Balloon catheters for body lumens
KR20220106852A (ko) 2013-07-26 2022-07-29 유니버시티 오브 아이오와 리써치 파운데이션 뇌 질환을 치료하기 위한 방법 및 조성물
MX2016001667A (es) 2013-08-08 2016-11-07 Global Bio Therapeutics Inc Dispositivo de sujecion para procedimientos minimamente invasivos y usos del mismo.
MX366880B (es) 2013-08-08 2019-07-29 Global Bio Therapeutics Inc Dispositivo de inyección para procedimientos mínimamente invasivos y usos del mismo.
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
WO2016090251A1 (en) 2014-12-05 2016-06-09 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
EP3250227A2 (en) 2015-01-28 2017-12-06 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
US11904072B2 (en) 2015-04-24 2024-02-20 Urotronic, Inc. Drug coated balloon catheters for nonvascular strictures
CN118236560A (zh) * 2015-04-24 2024-06-25 优敦力公司 用于非血管狭窄的药物涂布的球囊导管
MX2018002121A (es) 2015-08-17 2018-06-18 Alexion Pharma Inc Elaboracion de fosfatasas alcalinas.
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
JP2019513711A (ja) 2016-04-01 2019-05-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
NZ752760A (en) * 2016-09-22 2022-05-27 All Vascular Pty Ltd Devices and methods for vascular hyperperfusion of extravascular space
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS FOR TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
MX2021002198A (es) * 2018-08-24 2021-07-15 Spark Therapeutics Inc Secuencias de promotores optimizadas, construcciones de expresion libres de intrones y metodos de uso.
CN109504709B (zh) * 2018-11-28 2020-07-24 上海安民生物技术有限公司 白蛋白启动子驱动的白蛋白表达载体
CN113727750A (zh) 2019-02-22 2021-11-30 优敦力公司 用于体腔的药物涂布的球囊导管
US11498944B2 (en) 2020-01-31 2022-11-15 Janssen Pharmaceuticals, Inc. Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5674192A (en) * 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US6265387B1 (en) * 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US6416510B1 (en) * 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6290689B1 (en) * 1999-10-22 2001-09-18 Corazón Technologies, Inc. Catheter devices and methods for their use in the treatment of calcified vascular occlusions
US6135976A (en) * 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
AU2002212486B2 (en) * 2000-11-03 2007-10-04 Canji Incorporated Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids
JP2004532822A (ja) * 2001-03-14 2004-10-28 アビジェン， インコーポレイテッド ビリオンの管逆行感染による組換えアデノ随伴ウイルス媒介遺伝子移入
US20040009151A1 (en) * 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
WO2004001049A1 (en) * 2002-06-24 2003-12-31 Genzyme Corporation Methods of delivering gene therapy agents

Also Published As

Publication number Publication date
EP1827502A4 (en) 2008-01-16
EP1827502A2 (en) 2007-09-05
WO2006060641A2 (en) 2006-06-08
CN101068575A (zh) 2007-11-07
US20080025952A1 (en) 2008-01-31
JP2008521575A (ja) 2008-06-26
WO2006060641A3 (en) 2006-08-17
JP2012197297A (ja) 2012-10-18
BRPI0515819A (pt) 2008-08-05

Similar Documents

Publication Publication Date Title
MX2007006524A (es) Metodos para el suministro dirigido de material genetico al higado.
WO2003105757A3 (en) METHODS AND COMPOSITIONS FOR MEDIA-DEPENDENT BINDING OF A TARGET AGENT TO A TARGET
WO2007035474A3 (en) Transdermal delivery peptides and method of use thereof
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
WO2005030083A3 (en) Methods and products which utilize n-acyl-l-aspartic acid
WO2002020722A3 (en) Methods and compositions for in vitro targeting
WO2006014999A3 (en) Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
WO2001051604A3 (en) Methods for identifying anti-cancer drug targets
EP4174179A3 (en) Rna containing modified nucleosides and methods of use thereof
IL160015A0 (en) Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
WO2002051439A3 (en) Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
EP2465921A3 (en) Cardiac stem cells from biopsy
WO2008103993A3 (en) Compositions and methods for treating glycogen storage diseases
WO2005000245A3 (en) Compositions and methods for increasing telomerase activity
WO2006081158A3 (en) Predictive and therapeutic markers in overian cancer
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
WO2007016501A3 (en) Compositions and method for brain specific targeted delivery of therapeutic agents
SG166672A1 (en) Methods of down regulating target gene expression in vivo by introduction of interfering rna
WO2005051315A3 (en) On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
WO2008067049A3 (en) Particles for cell targeting
WO2008066886A3 (en) Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same
DK1526840T3 (da) Nanopartikler til DNA administration til et målorgan
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
WO2009067520A3 (en) Peptides specific for hepatocellular carcinoma cells and applications thereof
WO2002012440A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles